罕见系统性自身免疫病中内皮活化与功能障碍的生物标志物谱:心血管风险意义
本研究在未经治疗的局限性硬皮病、嗜酸性筋膜炎和(幼年)皮肌炎患者及对照组中检测38种与内皮功能和炎症相关的血清蛋白,发现疾病特异性生物标志物谱,活动期呈抗血管生成和干扰素驱动环境,治疗后不完全正常化,提示需监测血管生物标志物以评估长期心血管风险。
要点
- 嗜酸性筋膜炎和皮肌炎具有 distinct 生物标志物谱,共享干扰素、内皮活化及抗血管生成标志物上调。
- 活动期生物标志物谱与疾病活动相关,治疗后大部分正常化,但部分患者临床不活动期仍持续升高。
- 持续升高的标志物可能提示亚临床干扰素驱动炎症和/或内皮功能障碍,需进一步研究心血管风险监测。
核心结论
- 罕见慢性炎症性结缔组织病具有疾病特异性生物标志物谱,活动期表现为抗血管生成和干扰素驱动环境,治疗后不完全正常化。
研究设计与样本
- 研究纳入未经治疗的局限性硬皮病30例、嗜酸性筋膜炎8例、(幼年)皮肌炎34例,随访治疗中样本119份,对照65例,用多重免疫分析法检测38种血清蛋白。
主要发现
- 嗜酸性筋膜炎和皮肌炎具有 distinct 生物标志物谱,皮肌炎 signature 标志物为 galectin-9,嗜酸性筋膜炎为 CCL4、CCL18、CXCL9、fetuin、fibronectin、galectin-1 和 TSP-1。
- 局限性硬皮病中 CCL18、CXCL9 和 CXCL10 轻度升高。
- 皮肌炎和嗜酸性筋膜炎共享干扰素相关标志物(CCL2、CXCL10)、内皮活化标志物(VCAM-1)、抗血管生成标志物(angiopoietin-2、sVEGFR-1)及炎症/白细胞趋化标志物(CCL19、CXCL13、IL-18、YKL-40)上调,并伴有 Angiopoietin-Tie 受体系统和 VEGF-VEGFR 系统紊乱。
- 这些标志物谱与疾病活动相关,治疗期间大部分正常化;但部分患者临床不活动期仍持续升高 CXCL10、CXCL13、galectin-9、IL-18、TNFR2、VCAM-1 和/或 YKL-40。
临床怎么用
- 对罕见慢性炎症性结缔组织病患者,可考虑监测血管生物标志物以评估亚临床内皮功能障碍和长期心血管风险。
局限性
- 研究样本量较小(嗜酸性筋膜炎仅8例),且为单中心研究,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Vasculopathy is an important hallmark of systemic chronic inflammatory connective tissue diseases (CICTD) and is associated with increased cardiovascular risk. We investigated disease-specific biomarker profiles associated with endothelial dysfunction, angiogenic homeostasis and (tissue) inflammation, and their relation to disease activity in rare CICTD. METHODS: A total of 38 serum proteins associated with endothelial (dys)function and inflammation were measured by multiplex-immunoassay in treatment-naive patients with localized scleroderma (LoS, 30), eosinophilic fasciitis (EF, 8) or (juvenile) dermatomyositis (34), 119 (follow-up) samples during treatment, and 65 controls. Data were analysed by unsupervised clustering, Spearman correlations, non-parametric t test and ANOVA. RESULTS: The systemic CICTD, EF and dermatomyositis, had distinct biomarker profiles, with 'signature' markers galectin-9 (dermatomyositis) and CCL4, CCL18, CXCL9, fetuin, fibronectin, galectin-1 and TSP-1 (EF). In LoS, CCL18, CXCL9 and CXCL10 were subtly increased. Furthermore, dermatomyositis and EF shared upregulation of markers related to interferon (CCL2, CXCL10), endothelial activation (VCAM-1), inhibition of angiogenesis (angiopoietin-2, sVEGFR-1) and inflammation/leucocyte chemo-attraction (CCL19, CXCL13, IL-18, YKL-40), as well as disturbance of the Angiopoietin-Tie receptor system and VEGF-VEGFR system. These profiles were related to disease activity, and largely normalized during treatment. However, a subgroup of CICTD patients showed continued elevation of CXCL10, CXCL13, galectin-9, IL-18, TNFR2, VCAM-1, and/or YKL-40 during clinically inactive disease, possibly indicating subclinical interferon-driven inflammation and/or endothelial dysfunction. CONCLUSION: CICTD-specific biomarker profiles revealed an anti-angiogenic, interferon-driven environment during active disease, with incomplete normalization under treatment. This warrants further investigation into monitoring of vascular biomarkers during clinical follow-up, or targeted interventions to minimize cardiovascular risk in the long term.
引用
- Wienke J, Mertens JS, Garcia S, et al. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology (Oxford). 2021. PMID: 32810267. doi:10.1093/rheumatology/keaa270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。